Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
707 (USA) · Dr. Dubois
consented 2013-10-28
Adverse events
Moderate BLOOD CREATINE PHOSPHOKINASE INCREASED — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-11-26 (study day 30.0); relationship: POSSIBLE
Moderate BLOOD CREATINE PHOSPHOKINASE INCREASED — outcome: RECOVERED/RESOLVED; onset 2013-11-26 (study day 30.0); relationship: POSSIBLE
Moderate CONJUNCTIVITIS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-02-08 (study day 104.0); relationship: REMOTE
Moderate CONJUNCTIVITIS — outcome: RECOVERED/RESOLVED; onset 2014-02-08 (study day 104.0); relationship: REMOTE
Mild POSTNASAL DRIP — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-12-03 (study day 37.0); relationship: NONE
Mild POSTNASAL DRIP — outcome: RECOVERED/RESOLVED; onset 2013-12-03 (study day 37.0); relationship: NONE
Mild SINUS ARRHYTHMIA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-11-25 (study day 29.0); relationship: POSSIBLE
Mild SINUS ARRHYTHMIA — outcome: RECOVERED/RESOLVED; onset 2013-11-25 (study day 29.0); relationship: POSSIBLE
Data queries
No data queries.